Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00047853 · ClinicalTrials.gov registry record · NA
Brain Imaging Changes in Fear and Anxiety
A NA study, sponsored by National Institute of Mental Health (NIMH).
- Completed
- Registry status
- NA
- Development phase
- 1,080
- Enrollment target
NCT00047853: Completed NA study, sponsored by National Institute of Mental Health (NIMH).
NCT00047853 is a NA study that has completed, run by National Institute of Mental Health (NIMH). The registered enrollment target is 1,080 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (23% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00047853, a NA study, has completed, sponsored by National Institute of Mental Health (NIMH).
- COMPLETED
- Registry status
- NA
- Development phase
- 1,080 participants
- Enrollment target
Study Summary
The purpose of this study is to use brain imaging technology to investigate brain changes in people exposed to predictable versus unpredictable unpleasant stimuli. Unpleasant events that can be predicted evoke a response of fear, whereas unpredictable, unpleasant stimuli cause chronic anxiety not associated with a specific event. Information gained from this study may help in the development of more effective treatments for anxiety disorders. When confronted with fearful events, people eventually develop fear of specific cues that were associated with these events as well as to the environmental context in which the fearful event occurred. Evidence suggests that cued fear and contextual fear model different aspects of anxiety. However, studies that examine the way the brain affects expression of contextual fear have not been conducted. This study will use magnetic resonance imaging (MRI) or Magneto-encephalography (MEG) to compare the brain activity underlying fear brought on by predictable and unpredictable aversive stimuli.
Primary Outcome
The average bed nucleus of the stria terminalis (BNST) correlations between all averaged time series were extracted from the raters' individual masks. Blood Oxygenation Level Dependent (BOLD) signals were used to extract a mean time series from the BNST masks. This time series was correlated across the rest of the brain using 3dTcorr1D, which computes the correlation coefficient between each voxel time series. Raters were blinded to subject identity for subjective sensory effects at high field a
Interventions
- DEVICE Shock device
- DEVICE Acoustic startle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,080 participants |
| Start Date | 2002-11-04 |
| Est. Completion | 2022-07-28 |
| Phase | NA |
What the finished NCT00047853 record still lists
NCT00047853 is an interventional study that assigns participants to a tested intervention. Its 1,080 participants enrollment target places it among the larger protocols in the corpus, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (23% lower).
The record links to 0 conditions, and to 2 interventions - of which Shock device is the first listed.
NCT00047853 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00047853 about?
NCT00047853 is a clinical study titled "Brain Imaging Changes in Fear and Anxiety". The purpose of this study is to use brain imaging technology to investigate brain changes in people exposed to predictable versus unpredictable unpleasant stimuli. Unpleasant events that can be predicted evoke a response of fear, whereas unpredictable, unpleasant stimuli cause chronic anxiety not as...
What is the current status of trial NCT00047853?
This trial is currently completed. It is a NA study. The enrollment target is 1,080 participants. The study started on 2002-11-04. Estimated completion is 2022-07-28.
What interventions are being tested in trial NCT00047853?
The interventions under investigation include: Shock device (DEVICE), Acoustic startle (DEVICE).
Who is sponsoring clinical trial NCT00047853?
This trial is sponsored by National Institute of Mental Health (NIMH), which has 343 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00047853's enrollment target sits among peer trials
1,080 95th of 2000 higher than 1,906 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06074068 · 1,080 participants · NA
Father-Focused Intervention for Reducing Family Violence and Symptoms in Children
- NCT07213804 · 1,080 participants · Phase 3
A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer
- NCT07084883 · 1,076 participants
Pivotal Trial of an Automated AI-based System for Early Diagnosis and Prediction of Late Age-related Macular Degeneration
- NCT06658808 · 1,075 participants · NA
Efficacy-Implementation Study for PC CARES in Rural Alaska
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI